Derma Sciences Regions Map

Select your location from over 190 countries where Derma Sciences operates.

About Derma Sciences Inc.

Tissue Regeneration in Wound Care Across the Spectrum

Derma Sciences is a Tissue Regeneration Company at the forefront of research and innovation for the management of acute and chronic wounds, and burns. The products we bring to the market are in the best tradition of evidence-based medicine, helping clinicians around the world improve clinical outcomes.

With you in mind, our portfolio has grown to provide clinicians with solutions to assist with tissue regeneration - from the start of a wound through to wound closure. From MEDIHONEY®, to XTRASORB®, to BIOGUARD®, ALGICELL® Ag, TCC-EZ® and now, AMNIOEXCEL® and AMNIOMATRIX®, our intelligent, evidence-based products help to advance healing for patients suffering from complex chronic or acute wounds such as diabetic foot ulcers, venous leg ulcers, pressure ulcers and burns.

Company Highlights

Save The Date November 29th: TCC and Post-Surgical Use - Fireside Chat with Dr. Jeffrey Jensen, DPM, FACFAS - 22 November 2016

Join us for an interactive Fireside Chat with Dr. Jeffrey Jensen DPM FACFAS. Dr. Jensen will be focusing on specific topics each session that range from an introduction to Total Contact Casting (TCC) to using TCC with advanced therapies to manage hard to heal wounds. 30 minute presentation followed by 15 minute Q&A.

Best Practices for Treating DFUs - 25 May 2016

In this webcast, Dr. Snyder will review the evidence and best practices supporting the use of advanced modalities in the treatment of Diabetic Foot Ulcers (DFUs) to help save limbs while reducing cost. He will lead you through the latest published studies on the use of amniotic allografts for the protection and closure of chronic wounds and compare the pivotal Randomized Controlled Trials (RCTs) for the leading products.

Reimbursement Info Posted for AMNIOEXCEL Amniotic Allograft Membrane - 12 April 2016

Working with customers, the Derma Sciences Reimbursement Hotline has secured individual coverage approvals of AMNIOEXCEL® for use on chronic wounds from the following health plans: Medicare Advantage Plans and First Health Network. If you have patients who may benefit from use of AMNIOEXCEL®, and would like assistance with verifying benefits or the preauthorization process...

Multicenter RCT demonstrates AMNIOEXCEL® + SOC significantly increases the closure of chronic Diabetic Foot Ulcers - 7 March 2016

Derma Sciences, Inc. (Nasdaq:DSCI), a tissue regeneration company focused on advanced wound and burn care, announces that a peer-reviewed comparative clinical study of AMNIOEXCEL® Amniotic Allograft Membrane plus standard-of-care (SOC), compared with SOC alone, for the closure of hard-to-treat diabetic foot ulcers, has been published. The results are statistically significant and clinically meaningful, with the closure rate at six weeks in the AMNIOEXCEL® plus SOC treatment arm far exceeding the SOC alone treatment arm.

Use of Advanced Amniotic Tissue Products - 8 December 2015

The goal of this webinar is to review consensus guidelines and evidence-based medicine in the treatment of diabetic foot ulcers (DFUs) and other non-healing wounds. We will discuss the best time to initiate advanced therapeutics and clinical protocol for wound preparation. We will also review the science behind novel amniotic tissue products.